The Consortium Approach
Through the activities of the Cancer Immunotherapy Consortium (formerly the Cancer Vaccine Consortium), members whose companies are planning a launch of potential cancer vaccines advance their understanding of ways to achieve licensing and commercialization of this new wave of therapies. The Cancer Immunotherapy Consortium is focused on the ultimate goal of vaccine development—licensure and commercialization into a medical standard-of-care—and so is looking at advancing products through all phases of the process.
The Cancer Immunotherapy Consortium encourages and fosters greater community networking. Consortium members benefit from dynamic exchanges of data, standardization of assays, potential identification of combination therapies, and shared knowledge management. The overall benefit to members and to the medical community at large will be accelerated vaccine development and reduced costs and increased interaction and collaboration among its membership.
Cancer Immunotherapy Consortium members receive a variety of key benefits:
- Community
- Direct participation in the premier network of companies, organizations, and institutes actively working in the development and commercialization of cancer immunotherapies
- Cancer Immunotherapy Consortium Newsletter
- Cancer Immunotherapy Consortium Membership Directory
- Events
- Regular Consortium meetings
- Annual colloquia
- Special workshops on cancer vaccines
- Activism
- Legislation tracking and contacts
- Position papers, white papers, and presentations
- Media relations
In addition, each Cancer Immunotherapy Consortium member receives special representation in all Consortium activities:
- Participation in Consortium projects, committees, and working groups
- Invitation to Consortium meetings and workshops
- Complimentary subscription to the Cancer Research Institute's publications
- Acknowledgment of support in all program books and on our Web site
If your organization is exploring cancer immunotherapies and you wish to learn more about membership in the Cancer Immunotherapy Consortium, contact consortium@cancerresearch.org or call (800) 992-2623.
Back to Cancer Immunotherapy Consortium main page